In addition, JT has received approval for additional pediatric dosage and administration for CORECTIM Ointment 0.5%.
CORECTIM Ointment 0.25% and 0.5% are non-steroidal, JAK inhibitors that are expected to improve autoimmune and allergic diseases by inhibiting the action of JAKs, which play key roles in immune activation signalling in cells, by suppressing the overactivation of immune responses. In the Phase 3 comparative clinical study of CORECTIM Ointment 0.25% in pediatric patients with atopic dermatitis (aged 2 to < 16) conducted in
JT and Torii expect CORECTIM Ointment 0.25% and 0.5% to be a new option for the treatment of pediatric patients with atopic dermatitis in
ABOUT Atopic Dermatitis
Atopic dermatitis is a chronic and pruritic inflammatory skin disease. It is thought to develop through exposure to various irritants or allergens for patients with a physiological abnormality of the skin (dry skin and abnormal skin barrier function).
Contact:
Tel: +81-3-6636-2026
Email: jt.media.relations@jt.com
(C) 2021 Electronic News Publishing, source